Last updated: May 26, 2026
Magnesium Sulfate in Dextrose 5% (D5W) Plastic Container: Top Suppliers, Competitive Landscape, and Sourcing Risks
Executive summary: Suppliers of Magnesium Sulfate in Dextrose 5% (D5W) in plastic containers include branded and generic IV admixture manufacturers and API-to-finished-dose contract manufacturers that fill magnesium sulfate + D5W into polyolefin or EVA/COEX plastic infusion containers. In the US, availability is typically driven by (1) whether the product is marketed as an FDA-regulated drug product (vs. compounding using bulk), (2) container platform qualification, and (3) cold-start and hold-time constraints for IV solutions.
Action for procurement: treat this as a container-qualified, concentration-and-salt-specified supply chain item. Confirm the exact strength, salt form, container type, and NDC against the facility formulary before switching vendors.
Which companies supply Magnesium Sulfate in Dextrose 5% in plastic containers?
Featured snippet answer: The “supplier” universe usually falls into three categories:
- Finished-dose IV manufacturers that market an NDC for “magnesium sulfate in D5W” packaged in plastic.
- Contract manufacturers that fill and label under another firm’s label.
- Group purchasing organization and distributor inventory where the distributor may have multiple underlying NDC sources by lot.
How to identify the correct marketed product (not a compounding proxy)
Search and screen suppliers using these filters:
- Drug name: “magnesium sulfate” AND “dextrose 5%” (not just “magnesium sulfate injection”).
- Container: explicit “plastic container” (not glass).
- Strength/concentration: match the exact formulation strength (e.g., mg/mL of magnesium sulfate; D5W is typically 5% dextrose but the magnesium concentration must match).
- Salt form: magnesium sulfate heptahydrate is common for IV products, but the label should confirm.
- NDC: vendor availability is usually easiest to verify at the NDC level.
Supplier discovery workflow procurement teams actually use
- Pull your internal formulary list and capture NDC, concentration, container material, and manufacturer/labeler.
- Cross-check NDC for each therapeutic substitution.
- Use distributor ordering catalog entries to map to underlying NDCs.
- Validate that any replacement vendor has a compatible container (IV admixture tubing compatibility is sensitive to polymer type and bag thickness specs in some protocols).
What suppliers are listed on the FDA Orange Book for magnesium sulfate in D5W?
Featured snippet answer: For “magnesium sulfate in dextrose 5%” specifically, Orange Book coverage depends on whether the product is an FDA-approved reference-listed drug with listed patents. Many older IV generics may not have current patent listings or may be absent from active patent displays, so Orange Book use is sometimes limited. Use FDA NDC directory and labeler/manufacturer fields as the primary verification layer.
Where manufacturers appear in FDA systems
- NDC Directory / SPL: identifies labeler, strength, dosage form, and package details.
- Orange Book: identifies whether there is an RLD and whether there are listed patents (not required for every generic).
Commercial implication
If the Orange Book shows no active listed patents or no clear RLD, supplier churn is driven more by manufacturing capacity, container platform qualification, and supply interruptions than by IP.
Which formulations are “closest matches” for substitution, and which are different suppliers entirely?
Featured snippet answer: The closest formulation match must match:
- magnesium sulfate concentration
- carrier fluid (D5W vs. NS vs. sterile water)
- container type (plastic infusion container)
- label dosing instructions and total volume
Common supplier-side divergence points
- D5W vs. dextrose water alone: “dextrose 5% in water” variants differ in labeling and may not be equivalent to “magnesium sulfate in dextrose 5%.”
- Plastic container system: some products use different polymers or closure systems that can affect compatibility requirements.
- Concentration changes: magnesium sulfate content can vary by volume, and clinicians often require a specific mg dose per mL.
Practical procurement rule
Do not substitute based on “magnesium sulfate + D5W” alone. Substitute only after confirming the exact NDC or at minimum the strength-per-volume and container match.
How many suppliers exist for Magnesium Sulfate in Dextrose 5% plastic containers in the US?
Featured snippet answer: The number of active suppliers is typically small-to-moderate compared with higher-volume IV generics because the product is a specialty IV admixture (even when simple). The practical count often depends on:
- whether hospitals receive direct from manufacturers versus distributor lots,
- manufacturing site shutdowns,
- container-plant capacity,
- and whether a given firm markets multiple NDCs (different volumes).
What drives supplier count
- Container manufacturing availability: plastic infusion container production is concentrated in fewer global plants.
- Quality systems: IV solutions require consistent filtration, sterilization controls, and packaging QA.
- Demand pattern: magnesium sulfate shortages can be partially mitigated by alternate concentrations or alternative carrier fluids, which reduces urgency to keep many NDC SKUs in steady supply.
What are the most common shortage and lead-time risks for Magnesium Sulfate in D5W?
Featured snippet answer: The most common risk drivers are container-related, sterility/QA batch release, and supply interruptions of magnesium sulfate bulk or D5W sterile solution components.
Risk checklist
- Container platform changes: bag supplier substitution can affect lead time and paperwork.
- Batch release delays: sterility, endotoxin, and particulate control failures or re-testing can extend timelines.
- Bulk ingredient availability: magnesium sulfate supply fluctuations can ripple into finished IV concentration availability.
- Lot recall history: any lot-specific quality event can reduce available inventory quickly.
How do suppliers price and structure contracts for this IV product?
Featured snippet answer: Pricing typically follows NDC-level vendor contracts with:
- GPO contract tiers by distributor,
- spot market adjustments during shortage periods,
- and clauses tied to allocation or force majeure for container/ingredient constraints.
Contract levers procurement can use
- Keep a primary NDC supplier and at least one secondary NDC that is concentration-equivalent.
- Pre-approve alternate container configurations only if facility compatibility requirements allow.
- Lock allocation terms during shortage windows.
Which distributors usually control availability of Magnesium Sulfate in Dextrose 5% (plastic)?
Featured snippet answer: Availability is often controlled by major wholesalers and hospital group purchasing channels rather than by a long list of niche manufacturers. The supplier you see at order entry is commonly the distributor’s sourced NDC, which can shift without notice.
Operational implication
- Confirm what NDC you are ordering on each PO line.
- Track receipt NDC and lot numbers to avoid inadvertently switching to a non-equivalent product.
How does Magnesium Sulfate in D5W compare with alternatives (NS, sterile water, and other concentrations) for supplier substitution?
Featured snippet answer: Substitution across carriers changes clinical compatibility and dosing calculations, and it can also change the supplier list because the marketed NDCs differ.
Typical alternative pathways
- Magnesium sulfate in normal saline (NS) often has different suppliers and may have different shortage status.
- Magnesium sulfate in sterile water or dextrose-free solutions is separate from magnesium sulfate in D5W and may not be therapeutically interchangeable without protocol changes.
Procurement impact
When D5W supply tightens, organizations sometimes shift to NS products, which can relieve constraints but increases protocol workload and documentation risk.
What container specifications matter for sourcing Magnesium Sulfate in D5W?
Featured snippet answer: Container type and compatibility specs matter because this is a sterile IV solution delivered into infusion systems.
Container verification targets
- Plastic infusion container material (polyolefin/EVA blends depending on product)
- Closure and port system
- Total volume and labeled concentration
- Expiration dating and storage conditions
What is the manufacturing and IP barrier profile for suppliers of this drug?
Featured snippet answer: IP barriers are usually lower for mature IV generics like magnesium sulfate solutions, while manufacturing barriers (container platform qualification, sterile processing capability, and batch release controls) dominate.
Barrier categories
- Regulatory/CMC barrier: sterile fill-finish scale and container validation.
- Quality barrier: particulate control, pH/osmolality, and magnesium concentration uniformity.
- Supply barrier: bag/container availability and bulk input stability.
Key Takeaways
- Treat “magnesium sulfate in dextrose 5% in plastic container” as a specific NDC-level product, not a generic category.
- Supplier availability is driven more by container platform qualification and sterile batch release than by IP.
- Shortage and lead-time risk commonly originates from packaging/container supply and QA release events.
- For substitution, match magnesium concentration, carrier fluid, container type, and NDC to avoid clinical and procurement mismatches.
FAQs
1) Can I substitute Magnesium Sulfate in D5W with Magnesium Sulfate in NS if D5W is unavailable?
Only if your clinical protocol supports it and the facility confirms concentration and dosing equivalence.
2) What information should I capture to validate a supplier replacement for this IV product?
NDC, magnesium sulfate concentration (mg/mL), total volume, carrier fluid (D5W), and the plastic container/closure specs.
3) Why do suppliers sometimes change the package appearance while keeping the same drug name?
Different container vendors or closure systems can be used under labeling control, and distributor lots can reflect different packaging runs.
4) Are there fewer suppliers because this is in a plastic container?
Supply is constrained by container-plant qualification and sterile packaging capacity, which can reduce the number of active sources.
5) How do distributors shift supply during shortages?
They often allocate among underlying NDCs from multiple labelers; the safest approach is to lock purchase orders to the NDC and track received lot numbers.
